Clinical trials
Osteoarthritis trials in Italy with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 6 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Unknown status | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Istituto Ortopedico Rizzoli | 15 |
| Zimmer Biomet | 5 |
| Catholic University of the Sacred Heart | 2 |
| Fondazione Don Carlo Gnocchi ETS | 2 |
| I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 2 |
| Azienda Ospedaliero, Universitaria Ospedali Riuniti | 1 |
| DePuy International | 1 |
| Fin-Ceramica Faenza Spa | 1 |
| IRCCS Sacro Cuore Don Calabria di Negrar | 1 |
| Phoenix Kinetics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteoarthritis | 34 |
| Osteoarthritis, Knee | 11 |
| Pain | 4 |
| Ankylosis | 1 |
| Arthritis | 1 |
| Arthritis, Rheumatoid | 1 |
| Bone Diseases, Metabolic | 1 |
| Bone Malalignment | 1 |
| Fever | 1 |
| Joint Diseases | 1 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.